Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck

Cetuximab increases overall survival in patients with recurrent or metastatic squamous cell carcinomas of the head and neck. Reasonable treatment strategies include the use of first-line platinum, 5-fluorouracil and cetuximab combination, or cetuximab used following progression after a platinum-based regimen.

Download full article